Arch Bioscience Co

Hsiri Therapeutics is a pharmaceutical company based in Media, PA, dedicated to discovering and developing therapies for infections caused by drug-resistant bacteria and drug-resistant fungal diseases. Their research focuses on three main areas: mycobacterial infections, bacterial infections resistant to current treatments, and fungal infections resistant to drugs. With research concepts originating from Professor Marvin Miller at the University of Notre Dame, Hsiri Therapeutics has received support from the Department of Defense and the National Institutes of Health. Their discovery and research laboratories are located in South Bend, IN, with strong research collaborations in Bozeman, MT, and Singapore. Under the leadership of Chairman and CEO William Claypool, M.D., Hsiri Therapeutics aims to address the significant unmet medical need in the market by developing compounds targeting tuberculosis, non-tuberculous mycobacterial infections, drug-resistant bacterial infections, and drug-resistant fungal infections. With a team of experienced professionals, including Chief Scientific Officer Marvin Miller, Ph.D., Chief Financial Officer Ivan Joseph, MBA, and Chief Operating Officer Carrie Frey, MSC, MBA, Hsiri Therapeutics is committed to advancing antibiotic research and discovering new therapies for drug-resistant infections.Generated from the website

Incyte Corporation is a Delaware-based drug discovery and development company with a growing pipeline of oral compounds to treat HIV, inflammation, cancer and diabetes. Incyte has created an agile, highly focused and efficient research organization that has launched and fully staffed three internal discovery programs. The company trades on NASDAQ under the symbol INCY. It is headquartered in Wilmington, Del.

Neurokappa Therapeutics LLC is a Philadelphia-based company comprised of a team of scientists and business professionals dedicated to developing innovative medications for neurological diseases such as stroke, pain, and addiction. Leveraging their deep understanding of opioid receptors, they aim to create novel compounds that target these receptors, with potential therapeutic applications in stroke therapy, pain management, depression, and addiction therapy. The company's vision is to provide an effective alternative pathway for delivering medications for neurological diseases, particularly in out-of-hospital settings where intravenous access may not be readily available. With a focus on prioritizing the efficacy of action over the mechanism of actions, Neurokappa Therapeutics LLC is committed to continuously pursuing both scientific discoveries and the development of new indications for existing medications.Generated from the website